Gavi, the Vaccine Alliance has begun evaluating emergency financing mechanisms and vaccine development options as the Ebola outbreak linked to the Bundibugyo virus strain escalates across the Democratic Republic of Congo (DRC) and Uganda, raising fresh concerns over regional health security and outbreak preparedness.
In a statement issued from Geneva on Thursday, Gavi said the outbreak, already declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization and a Public Health Emergency of Continental Security (PHECS) by Africa Centres for Disease Control and Prevention, underscores the urgent need for coordinated international intervention.
Health authorities have reported more than 500 suspected infections and over 130 deaths in the DRC, while confirmed cases have also emerged in Kampala, Uganda, signaling cross-border transmission risks and a rapidly evolving public health crisis.
The outbreak is being driven by the Bundibugyo strain of Ebola virus disease (BVD), for which there are currently no approved vaccines or therapeutics. Gavi warned that the situation is further complicated by population displacement, insecurity, and limited healthcare access in affected communities.
“The outbreak requires a country-led, highly coordinated and evidence-based response,” the alliance said.
Vaccine Supply Constraints Raise Global Health Concerns
Gavi noted that while it finances the global Ebola vaccine stockpile, existing licensed vaccines are designed for the Zaire ebolavirus strain and not the Bundibugyo variant currently responsible for the outbreak.
The alliance cautioned that evidence on cross-protection remains extremely limited, meaning any deployment of existing Ebola vaccines would require further scientific assessment, adherence to WHO guidance, and informed consent from affected populations.
The development exposes a significant gap in global epidemic preparedness, particularly for less common Ebola strains that have historically received lower levels of research funding and commercial interest.
Experimental Vaccine Candidates Under Review
Gavi said it is working alongside Coalition for Epidemic Preparedness Innovations, WHO, UNICEF, the World Bank, Pandemic Fund, and private-sector partners to assess experimental vaccine candidates currently in development.
Among the leading candidates identified by WHO are:
- An rVSV-platform vaccine targeting Bundibugyo ebolavirus, based on the same technology used in the licensed Ervebo vaccine for Zaire Ebola. However, no doses are currently available for clinical trials, and production timelines are estimated at six to nine months.
- A ChAdOx-platform candidate vaccine, using technology similar to some COVID-19 vaccines. However, no animal or human trial data currently exists for the vaccine’s effectiveness against Bundibugyo virus disease.
The absence of ready-to-deploy vaccines highlights ongoing structural challenges in financing vaccine research for outbreak-prone diseases with uncertain commercial returns.
Gavi Weighs Use of $500 Million Emergency Fund
The alliance is also evaluating the possible deployment of its First Response Fund (FRF), a $500 million emergency financing mechanism established after lessons learned from the COVID-19 pandemic.
The FRF was designed to accelerate access to vaccines outside Gavi’s standard portfolio during global health emergencies through mechanisms such as advance purchase commitments and at-risk manufacturing support.
Under the framework, up to $50 million can be approved directly by Gavi’s Chief Executive Officer for rapid emergency response, while larger disbursements require board approval.
According to Gavi, the fund could be used to incentivise vaccine manufacturers to accelerate production of promising Bundibugyo vaccine candidates while also supporting routine immunisation systems in affected countries.
The mechanism was previously deployed during the recent mpox outbreak, where it helped secure 500,000 vaccine doses and supported outbreak logistics with nearly $10 million in delivery funding.
Economic and Investment Implications
The resurgence of Ebola in Central and East Africa is expected to place additional pressure on fragile healthcare systems and could impact trade, transport, mining activities, and investor confidence across parts of the region if containment efforts falter.
Public health analysts say the outbreak also serves as a reminder of the growing intersection between global health security and economic resilience, especially as governments and multilateral institutions face tightening development finance conditions.
For vaccine manufacturers and biotech firms, the outbreak may also trigger renewed interest in neglected disease research and public-private funding models aimed at strengthening Africa’s epidemic preparedness infrastructure.
